Oxytocin: its role in benign prostatic hyperplasia via the ERK pathway

Huan Xu, Shi Fu, Yanbo Chen, Qi Chen, Meng Gu, Chong Liu, Zhiguang Qiao, Juan Zhou, Zhong WangClinical 2017 · DOI

Abstract

The aim of the present study was to evaluate oxytocin and benign prostatic hyperplasia (BPH), and study the cell signalling mechanism. Investigation was performed in patients about the correlation between oxytocin level and BPH. Mice were injected with oxytocin or oxytocin antagonist for 2 weeks and the prostate morphology was studied after their sacrifice. Furthermore, <i>in vitro</i> experiments were performed to evaluate the oxytocin effect through the MEK/ERK/RSK pathway. Oxytocin was significantly elevated in the serum and prostate tissue of patients with BPH, and a positive correlation with prostate volume indicated. In the animal experiments, prostate enlargement was observed in the oxytocin-treated group, whereas oxytocin antagonist reduced prostate hyperplasia. The <i>in vitro</i> study confirmed this result and also revealed activation of the MEK/ERK/RSK pathway. Oxytocin is highly expressed in the serum and prostate tissue of patients with BPH. In addition, oxytocin aggravates BPH and the oxytocin-induced proliferative effect on prostatic cells is mediated through the MEK/ERK/RSK pathway, at least partly. Thus, the hypothalamic regulation may be involved in development of BPH, which may open a new door to more medications for BPH in the future.
BibTeX
@inproceedings{xu2017oxytocin,
  author = {Huan Xu and Shi Fu and Yanbo Chen and Qi Chen and Meng Gu and Chong Liu and Zhiguang Qiao and Juan Zhou and Zhong Wang},
  title = {{Oxytocin: its role in benign prostatic hyperplasia via the ERK pathway}},
  booktitle = {Clinical},
  year = {2017},
  doi = {10.1042/cs20170030},
}

Loading related content...

Figure